Home | Volume 43 | Article number 20

Case report

Acute dapsone poisoning with methemoglobinemia: a case report

Acute dapsone poisoning with methemoglobinemia: a case report

Hamza El Hamzaoui1,&, Idriss Chajai1, Mohamed Chahidi El Ouazzani1, Abdelkader Benhalima1, Manal El Arfaoui1, Mustapha Alilou1


1Emergency Department, Faculty of Medicine and Pharmacy of Rabat, University Mohamed V of Rabat, CHU Ibn Sina, Rabat, Morocco



&Corresponding author
Hamza El Hamzaoui, Emergency Department, Faculty of Medicine and Pharmacy of Rabat, University Mohamed V of Rabat, CHU Ibn Sina, Rabat, Morocco




Methemoglobinemia is a common complication of dapsone poisoning. Its´ treatment usually relies on methylene blue infusion. The aim of this study was to report a case of an acute dapsone poisoning with methemoglobinemia treated only with ascorbic acid and activated charcoal. A 16-year-old female voluntary ingested 3 grams of dapsone in an attempt of suicide and presented with desaturation and tachypnea. Lab findings were compatible with methemoglobinemia. After two days of treatment with ascorbic acid and activated charcoal, we observed the disappearance of desaturation and tachypnea. Methemoglobinemia can be treated with ascorbic acid and activated charcoal in limited resource settings.



Introduction    Down

Methemoglobinemia is defined by a level of methemoglobin superior to 1.5 g/dl [1]. It is a life threatening situation in which the severity of symptoms depends on the methemoglobin levels. It can be caused by exposure to dapsone [2]. The diagnosis relies on arterial or venous gas with co-oximetry and its management implies methylene blue infusion. We present a case of a 16-year-old female with acute dapsone poisoning presenting with methemoglobinemia, treated by ascorbic acid and activated charcoal rather than methylene blue, with a good outcome.



Patient and observation Up    Down

Patient information: a 16-year-old female with no medical history was admitted to the intensive care unit of the emergency department, 9 hours after the voluntary ingestion of 3 grams of dapsone, in an attempt of suicide. The parents report a violent conflict with their daughter and the patient declares that she no longer wants to commit suicide.

Clinical findings: the patient presented with tachypnea at 41 cycles per minute, and desaturation at 68% on room air with cyanosis (Figure 1). Her heart rate was 110 beats per minute, with a blood pressure of 114/69 with no signs of shock or cardiac failure. Pulmonary and cardiac auscultation was unremarkable. The patient was conscient and reported dizziness and headaches.

Timeline of current episode: 10th of November 2021 at 1 a.m.: ingestion of 3 grams of dapsone; 10th of November 2021 at 10 a.m.: admission of the patient with cyanosis desaturation and tachypnea, initiation of activated charcoal; 10th of November 2021 at 4 p.m.: results of methemoglobin levels received, diagnosis of methemoglobinemia made; 10th of November 2021 at 5 p.m.: initiation of ascorbic acid; 12th of November 2021 at 11 a.m.: normal saturation, disappearance of cyanosis and tachypnea.

Diagnostic assessment: chest X-ray and electrocardiogram were performed with no abnormalities found. Electrolytes, renal function and the hemogram were normal (Table 1). Arterial blood gas was realized while the patient received oxygen through a non rebreather mask and showed hypocapnia resulting from hyperventilation, with hyperoxia. The methemoglobin assay wasn´t available in our hospital´s lab, and was carried out in another laboratory. It showed a methemoglobin percentage of 13.7%.

Diagnosis: the results were consistent with methemoglobinemia given the methemoglobin percentage of 13.7%, the saturation gap and the cyanosis.

Therapeutic interventions: our patient received oxygen through a non rebreather mask. Intravenous methylene blue wasn´t available. Our patient received 1 gram of ascorbic acid twice a day orally, and a loading dose of 50 grams of activated charcoal orally, followed by 25 grams every 6 hours orally.

Follow-up and outcome of interventions: we observed the disappearance of cyanosis and tachypnea, with normal saturation on room air after two days of treatment after progressive weaning from oxygen. No hemolytic anemia was observed during her stay in the intensive care unit. After stabilization, the patient was transferred to the mental health unit for further management of her suicide attempt.

Patient perspective:I hope there will be no complications. Overall, the treatment wasn´t painful given it consisted mainly of oral intake´´.

Informed consent: the patient and her parents gave informed consent.



Discussion Up    Down

Methemoglobinemia is known to be an adverse effect of dapsone [1-3]. Its signs and symptoms are summarized in Table 2. They include headaches, cyanosis, dizziness, tachypnea and low pulse oximeter readings [3]. An important gap between SpO2 and SaO2, known as saturation gap and refractory hypoxemia measured with SpO2 are additional clues supporting the diagnosis of methemoglobinemia [4]. The diagnosis is confirmed by arterial or venous blood gas with co-oximetry, which determines the concentration or the percentage of methemoglobin.

Management of methemoglobinemia relies on methylene blue infusion. Methylene blue is an exogenous electron donor which enhances the reduction of methemoglobinemia by the action of nicotinamide adenine dinucleotide phosphate hydrogen methemoglobin (NADPH-MetHb) [4]. This treatment is contraindicated in the case of G6PD deficiency [5]. Ascorbic acid administration is considered as an alternative to methylene blue therapy, when the latter is contraindicated or not available [5]. Furthermore, dapsone is known to be adsorbed onto activated charcoal. In dapsone poisoning, multiple dose activated charcoal can be administered. It interrupts enteroenteric and hepatoenteric circulation, thus allowing secondary elimination of toxic agents [6].

In this case, the dapsone exposure, the patient´s physical examination, the saturation gap and the increased methemoglobin percentage confirmed the diagnosis of methemoglobinemia. We were limited in our approach to this case, given the unavailability of the methemoglobinemia level assay in our hospital´s laboratory and the methylene blue therapy. We initiated as fast as possible our treatment with the ascorbic acid and multiple dose activated charcoal treatment, thus improving our patient´s outcome and prognosis.



Conclusion Up    Down

Our patient with methemoglobinemia secondary to dapsone poisoning, had an excellent clinical outcome with disappearance of symptoms and signs of methemoglobinemia with the sole use of ascorbic acid and activated charcoal. This therapy can be used in the absence of methylene blue infusion or in the case of its contraindication.



Competing interests Up    Down

The authors declare no competing interest.



Authors' contributions Up    Down

HEH, MCEO, AB, and MEA: patient management; HEH, IC, and MCEO: data collection; HEH and IC: manuscript drafting; HEH and MA: manuscript revision. All the authors have read, and approved the final version of the manuscript.



Tables and figure Up    Down

Table 1: biological findings

Table 2: signs and symptoms of methemoglobinemia correlated with methemoglobin percentage in plasma

Figure 1: cyanosis on our patient´s lips



References Up    Down

  1. Wright RO, Lewander WJ, Woolf AD. Methemoglobinemia: etiology, pharmacology, and clinical management. Ann Emerg Med. 1999;34(5):646-656. PubMed | Google Scholar

  2. Kurien G, Jamil RT, Preuss CV. Dapsone. In: StatPearls. Treasure Island (FL): StatPearls Publishing. 2022. PubMed | Google Scholar

  3. Iolascon A, Bianchi P, Andolfo I, Russo R, Barcellini W, Fermo E et al. Recommendations for diagnosis and treatment of methemoglobinemia. Am J Hematol. 2021 Dec 1;96(12):1666-1678. PubMed | Google Scholar

  4. Ludlow JT, Wilkerson RG, Nappe TM. Methemoglobinemia. In: StatPearls. Treasure Island (FL): StatPearls Publishing. 2019. PubMed | Google Scholar

  5. Sahu KK, Mishra AK. Role of ascorbic acid in dapsone induced methemoglobinemia. Clin Exp Emerg Med. 2019 Mar;6(1):91-92. PubMed | Google Scholar

  6. Zellner T, Prasa D, Färber E, Hoffmann-Walbeck P, Genser D, Eyer F. The use of activated charcoal to treat intoxications. Dtsch Arztebl Int. 2019 May 3;116(18):311-317. PubMed | Google Scholar